gimli

GAUDIUMIVF stock AI analysis

GAUDIUMIVF Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers

GAUDIUM IVF N WOMEN H L is a small-cap stock in Healthcare. This Gimli page shows the latest available GAUDIUMIVF price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.

Analyze with AI Open interactive GAUDIUMIVF stock page

Price

₹116.22

1W return

+0.83%

1M return

-1.81%

3M return

+9.03%

6M return

+22.62%

1Y return

n/a

Market cap

₹845.93 cr

34.54

5.55

ROE

+24.66%

ROCE

+29.28%

RSI

45.07

Turnover

₹1.81 cr

Why it can matter in screens

Momentum: GAUDIUMIVF is below 50DMA, below 200DMA; RSI is 45.07.
Returns: 1D +1.25%, 1W +0.83%, 1M -1.81%, 3M +9.03%, 1Y n/a.
Trend levels: 52W high ₹163.18, 52W low ₹99.54, off high -28.78%.
Liquidity: latest turnover is ₹1.81 cr; volume vs 20D is +0.94%.
Valuation/profitability: PE 34.54, PB 5.55, ROE +24.66%, ROCE +29.28%.
Growth: 3Y sales CAGR +33.11%, 3Y profit CAGR +21.86%.

Quick Answers

What is the latest GAUDIUMIVF stock price?

The latest stored price for GAUDIUMIVF is Rs 116.22 as of 2026-09-18.

Is GAUDIUMIVF above its 50DMA and 200DMA?

GAUDIUMIVF is below 50DMA, below 200DMA. The latest 50DMA is 127.90 and the latest 200DMA is n/a.

What are GAUDIUMIVF PE, ROE and ROCE?

GAUDIUMIVF has PE 34.54, ROE +24.66%, and ROCE +29.28% in Gimli's latest available snapshot.

How has GAUDIUMIVF performed recently?

GAUDIUMIVF has returned -1.81% over 1 month, +9.03% over 3 months, and n/a over 12 months in the latest stored data.

Is this stock page investment advice?

No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.

Financials and Ownership

Quarterly income statement

Period	Revenue	EBITDA	PAT	EPS
2026-03-31	30.35 cr	12.35 cr	8.36 cr	1.34
2025-12-31	24.51 cr	6.65 cr	3.63 cr	0.50
2025-09-30	31.88 cr	13.91 cr	9.38 cr	1.53
2025-03-31	26.92 cr	8.96 cr	6.46 cr	0.89
2024-12-31	14.42 cr	5.66 cr	3.40 cr	0.47

Annual income statement

Year	Revenue	EBITDA	PAT	EPS
2026-03-31	104.36 cr	38.24 cr	24.49 cr	3.92
2025-03-31	70.72 cr	28.87 cr	19.18 cr	2.63
2024-03-31	47.89 cr	19.54 cr	10.32 cr	1.42
2023-03-31	44.24 cr	20.09 cr	13.53 cr	1.86
2022-03-31	n/a	n/a	n/a	1.11

Balance sheet

Period	Assets	Cash	Debt	Equity
2026-03-31	193.10 cr	8.79 cr	24.57 cr	152.30 cr
2025-03-31	88.51 cr	7.21 cr	20.61 cr	46.30 cr
2024-03-31	51.01 cr	11.86 cr	17.40 cr	26.99 cr
2023-03-31	36.63 cr	15.06 cr	11.55 cr	22.73 cr

Cash flow

Period	OCF	FCF	Cash change
2026-03-31	7.25 cr	0.53 cr	n/a
2025-03-31	8.72 cr	-0.16 cr	n/a
2024-03-31	3.44 cr	0.65 cr	n/a
2023-03-31	23.85 cr	8.60 cr	n/a
2022-03-31	n/a	n/a	n/a

Shareholding Trend

Period	Promoter	FII/FPI	DII	MF	Retail	Pledge
2026-06-30	+71.29%	+3.02%	+2.22%	+0.00%	+23.47%	+0.00%
2026-03-31	+71.29%	+6.70%	+2.62%	+0.00%	+19.39%	+0.00%
2026-02-26	+71.29%	+9.24%	+5.11%	+0.00%	+14.36%	+0.00%

Industry Peers

Symbol	Name	Mcap	PE	ROE	1Y
SUNPHARMA	SUN PHARMACEUTICAL IND L	440,829.82 cr	36.388220	+15.50%	+11.45%
DIVISLAB	DIVI S LABORATORIES LTD	248,876.81 cr	85.407280	+18.37%	+53.39%
TORNTPHARM	TORRENT PHARMACEUTICALS L	163,807.57 cr	75.106636	+17.33%	+35.67%
APOLLOHOSP	APOLLO HOSPITALS ENTER. L	128,608.22 cr	65.670049	+21.03%	+13.94%
ZYDUSLIFE	ZYDUS LIFESCIENCES LTD	116,723.14 cr	26.011308	+16.04%	+10.70%
CIPLA	CIPLA LTD	112,647.78 cr	33.401961	+10.25%	-11.64%
LAURUSLABS	LAURUS LABS LIMITED	105,487.98 cr	96.587446	+21.77%	+111.64%
MAXHEALTH	MAX HEALTHCARE INS LTD	102,122.47 cr	70.799892	+14.33%	-10.58%

Try these prompts

Analyze GAUDIUM IVF N WOMEN H L with valuation, momentum and industry peers
Compare GAUDIUMIVF with other Healthcare stocks
Show small-cap stocks in Healthcare above 50DMA with positive 1M return
Find Healthcare stocks with improving momentum and reasonable valuation

Related screen ideas

Data snapshot: 2026-09-18. Not investment advice.